

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Duft, et al.

Serial No.: 08/870,762

Filed: June 6, 1997

Title: METHODS FOR TREATING OBESITY

Group Art Unit: 1645

Examiner: S. Devi

#37  
Linda  
12/18/02

RECEIVED

DEC 06 2002

TECH CENTER 1600/2900

DECLARATION UNDER 37 C.F.R. § 1.131

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Dear Sir:

1. Having reviewed the May 30, 2002 Office Action in the above-captioned case, we understand that pending claims 1-14 in the subject patent application have been rejected by the U.S. Patent and Trademark Office ("PTO") for alleged lack of novelty in view of an Abstract bearing the date "May 1997" (Thompson *et al.*, *Diabetes*, 46(Supp. 1):30A). A copy of this document, which was included in an Abstract Book for the 57<sup>th</sup> Scientific Sessions of the American Diabetes Association (the "ADA," publisher of *Diabetes*) in Boston, MA on June 21-24, 1997, is attached hereto as Exhibit A and is hereinafter referred to as the "Thompson/Pearson/Schoenfeld/Kolterman Abstract."

2. The Thompson/Pearson/Schoenfeld/Kolterman Abstract describes clinical experiments undertaken by Amylin Pharmaceuticals. All of the named authors, Robert Thompson, LeeAnne Pearson, and Steven Schoenfeld, as well as Dr. Kolterman, were employees of Amylin Pharmaceuticals, Inc. at the time the experiments described therein were planned and

carried out, prior to its publication, including experiments designed and supervised by Dr. Kolterman relating to weight loss.

3. Assuming for the purposes of this Declaration the assertion of the Patent Office that claims 1-14 of the present application first filed on June 6, 1997 were anticipated by the Thompson/Pearson/Schoenfeld/Kolterman Abstract, we thus note that the information referenced in the Thompson/Pearson/Schoenfeld/Kolterman Abstract relates to work done under the direction and supervision of one of the undersigned co-inventors, Dr. Orville Kolterman at Amylin Pharmaceuticals, who is also its co-author.

4. Attached Exhibits B, C, and D demonstrate, furthermore, that the subject matter of the Thompson/Pearson/Schoenfeld/Kolterman Abstract relied on by the PTO was based on a reduction to practice of the subject matter thereof not later than January 6, 1997.

5. A copy of the Abstract Preparation Guidelines governing submission of this Abstract to the ADA for the 57<sup>th</sup> Scientific Sessions is attached hereto as Exhibit B, showing that the Thompson/Pearson/Schoenfeld/Kolterman Abstract was prepared prior to January 6, 1997, and submitted to the ADA on or before January 6, 1997, for the 57<sup>th</sup> Scientific Sessions in Boston, MA on June 21-24, 1997. As evidenced by Exhibit B, the ADA required that abstracts be received by January 6, 1997 in order to be published in the Abstract Book for the 57<sup>th</sup> Annual Meeting. Paragraph 33 in the Exhibit B Abstract Preparation Guidelines specified that any abstracts submitted after January 6, 1997 were deemed "late-breaking research" abstracts that would "not be published in the Abstract Book" nor "appear in the Final Program because of printing deadlines." As specified in Paragraph 7 of Exhibit B, the ADA did not permit changes to submitted Abstracts.

6. Attached as Exhibit C is a copy of the Abstract Submission form that accompanied the Thompson/Pearson/Schoenfeld/Kolterman Abstract submitted to and received by the ADA on or before January 6, 1997. As evidenced by Exhibit C, the Thompson/Pearson/Schoenfeld/Kolterman Abstract was not submitted as a "late-breaking research" abstract. Thus, in accordance with the Exhibit B Abstract Preparation Guidelines, it was included in the May 1997 *Diabetes* Abstract Book cited by the PTO. Further, the content of Abstract submitted to the ADA (Exhibit C) is the same as the published Abstract bearing the date "May 1997" (Thompson *et al.*, *Diabetes*, 46(Supp. 1):30A) (Exhibit A).


7. Attached as Exhibit D is a letter of acceptance from the ADA to Robert Thompson dated March 17, 1997, establishing that the Abstract submitted to and received by the ADA on or before January 6, 1997 was reviewed and accepted for publication not latter March 17, 1997.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 101 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the above-identified U.S. Patent Application or any Patent issued thereon.

Dated: November 27, 2002

  
Orville G. Kolterman, M.D.

Dated: ~~November~~ December 2, 2002

  
Bradford J. Duft

# diabetes

A JOURNAL OF THE  
AMERICAN DIABETES  
ASSOCIATION®

[www.diabetes.org/diabetes](http://www.diabetes.org/diabetes)



## ABSTRACT BOOK

57th Annual Meeting and Scientific Sessions  
Saturday, June 21 — Tuesday, June 24, 1997

Hynes Convention Center  
Boston, Massachusetts

|   |         |
|---|---------|
| 1996-1997 Officers and Board of Directors           | i       |
| Past Officers                                       | iv      |
| Awards Banquet                                      | v       |
| Banting Medal for Scientific Achievement            | vi      |
| Outstanding Scientific Achievement Award            | vii     |
| Past National Achievement Award Recipients          | viii    |
| 1996-1997 Professional Section Council Chairs       | x       |
| 1996-1997 Research Awards and Grants                | xi      |
| 1996-1997 Scientific Sessions Meeting Committee     | xiv     |
| 1996-1997 Abstract Reviewers                        | xiv     |
| General Information                                 | xv      |
| Satellite Program                                   | xvii    |
| Scientific Sessions Day-At-A-Glance                 | xix     |
| Faculty Roster                                      | xxiii   |
| Scientific Sessions Program—Saturday, June 21, 1997 | xxviii  |
| Scientific Sessions Program—Sunday, June 22, 1997   | xxxviii |
| Scientific Sessions Program—Monday, June 23, 1997   | 1       |
| Scientific Sessions Program—Tuesday, June 24, 1997  | lxi     |
| Maps of Meeting Sites                               | lxi     |
| Commercial Exhibits                                 | lxxvii  |
| Duality of Interest Information                     | lxxvii  |
| Abstracts—Presented and Published                   | 1A      |
| Abstracts—Published Only                            | 289A    |
| Subject Index                                       | 393     |
| Author Index  | 407     |



**Pramlintide, an Analog of Human Amylin Improves Glycemic Control in Patients with Type II Diabetes Requiring Insulin.**

**ROBERT THOMPSON\*<sup>1</sup>, LEEANNE PEARSON\*<sup>1</sup>, STEVEN SCHOENFELD\*<sup>1</sup>, ORVILLE KOLTERMAN\*<sup>1</sup>. *San Diego, CA***

The effects of 4 weeks of subcutaneous administration of pramlintide, (Pr) an analog of human amylin, on glycemic control in 203 patients with Type II diabetes mellitus requiring insulin were examined in a randomized, double-blind, placebo-controlled, parallel-group trial. Statistically significant reductions in serum fructosamine concentration were observed in the Pr 30 µg QID group ( $17.5 \pm 4.9$  µmol/L), the Pr 60 µg TID group ( $24.1 \pm 4.9$  µmol/L) and the Pr 60 µg QID group ( $22.6 \pm 4.1$  µmol/L) compared to placebo (PBO) ( $3.5 \pm 3.8$  µmol/L). There also were statistically significant shifts in the proportion of patients with an abnormal serum fructosamine concentration at baseline that normalized at Week 4 within the Pr 60 µg TID group (28%) and the Pr 60 µg QID group (31%) compared to PBO (10%). Consistent with the reduction in fructosamine, there were also statistically significant reductions in HbA<sub>1c</sub> in the Pr 30 µg QID group ( $0.53 \pm 0.07\%$ ), the Pr 60 µg TID group ( $0.58 \pm 0.07\%$ ) and the Pr 60 µg QID group ( $0.51 \pm 0.08\%$ ) compared to placebo ( $0.27 \pm 0.08\%$ ). Based on RBC lifespan, and assuming stable glycemic control, these reductions in HbA<sub>1c</sub> in the Pr groups should increase over the following 2-3 months. The reductions in fructosamine and HbA<sub>1c</sub> were accompanied by a statistically significant reduction in fasting total and LDL cholesterol. In contrast to treatment with insulin alone, there were trends towards decreased body weight in the Pr 60 µg TID and 60 µg QID groups. Furthermore, the incidence of hypoglycemia was no greater in any Pr group than in placebo. In conclusion, measurement of similar changes in both serum fructosamine concentration and HbA<sub>1c</sub> suggests that pramlintide therapy for 28 days improves glycemic control in patients with Type II diabetes mellitus requiring insulin.

# diabetes

A JOURNAL OF  
THE AMERICAN  
DIABETES  
ASSOCIATION.

**Abstract Form  
for 57th Scientific  
Sessions Included;  
Submission  
Deadline Is  
January 6, 1997**

## PERSPECTIVES IN DIABETES

Leptin: the tale of an obesity gene J.F. CARO, M.K. SINHA, J.W. KOLACZYNSKI, P.L. ZHANG, AND R.V. CONSIDINE 1455

## ORIGINAL ARTICLES

Disturbed development of the preimplantation embryo in the insulin-dependent diabetic BB/E rat R.G. LEA, J.E. MCCracken, S.S. MCINTYRE, W. SMITH, AND J.D. BAIRD 1463

Evidence for dissociation of insulin stimulation of blood flow and glucose uptake in human skeletal muscle: studies using [ $^{15}\text{O}$ ]H<sub>2</sub>O, [ $^{18}\text{F}$ ]fluoro-2-deoxy-D-glucose, and positron emission tomography M. RAITAKARI, P. NUUTILA, U. RUOTSALAINEN, H. LAINE, M. TERÄS, H. IIDA, S. MÄKIMATTILA, T. UTRAIENEN, V. OIKONEN, H. SIPILÄ, M. HAAPARANTA, O. SOLIN, U. WEGELIUS, J. KNUUTI, AND H. YKI-JÄRVINEN 1471

The human glucokinase gene  $\beta$ -cell-type promoter: an essential role of insulin promoter factor 1/PDX-1 in its activation in HIT-T15 cells H. WATADA, Y. KAJIMOTO, Y. UMAYAHARA, T.-A. MATSUOKA, H. KANETO, Y. FUJITANI, T. KAMADA, R. KAWAMORI, AND Y. YAMASAKI 1478

Glycation of insulin in the islets of Langerhans of normal and diabetic animals Y.H.A. ABDEL-WAHAB, F.P.M. O'HARTE, H. RATCLIFF, N.H. MCLENAGHAN, C.R. BARNETT, AND P.R. FLATT 1489

Pregnant diabetic rats fed the antioxidant butylated hydroxytoluene show decreased occurrence of malformations in offspring U.J. ERIKSSON AND C.M. SIMAN 1497

Altered insulin secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12 M.M. BYRNE, J. STURIS, S. MENZEL, K. YAMAGATA, S.S. FAJANS, M.J. DRONSFIELD, S.C. BAIN, A.T. HATTERSLEY, G. VELHO, P. FROGUEL, G.I. BELL, AND K.S. POLONSKY 1503

Responses of leptin to short-term fasting and refeeding in humans: a link with ketogenesis but not ketones themselves J.W. KOLACZYNSKI, R.V. CONSIDINE, J. OHANNESIAN, C. MARCO, I. OPENTANOVA, M.R. NYCE, M. MYINT, AND J.F. CARO 1511

Muscle subcellular localization and recruitment by insulin of glucose transporters and Na<sup>+</sup>-K<sup>+</sup>-ATPase subunits in transgenic mice overexpressing the GLUT4 glucose transporter T. RAMLAL, H.S. EWART, R. SOMWAR, R.O. DEEMS, M.A. VALENTIN, D.A. YOUNG, AND A. KLIP 1516

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM J. RACHMAN, F.M. GRIBBLE, B.A. BARROW, J.C. LEVY, K.D. BUCHANAN, AND R.C. TURNER 1524

Inhibition of mitochondrial complex I may account for IDDM induced by intoxication with the rodenticide Vacor M. DEGLI ESPOSTI, A. NGO, AND M.A. MYERS 1531

Genetic control of giant perivascular space formation in the thymus of NOD mice E. COLOMB, W. SAVINO, L. WICKER, L. PETERSON, M. DARDENNE, AND C. CARNAUD 1535

$\beta$ -cell growth and mass are preserved in long-term syngeneic islet transplantation in streptozocin-induced diabetic Lewis rats V. NÄCHER, M. RAURELL, J.F. MERINO, O. ARANDA, J. SOLER, AND E. MONTANA 1541

Insulin sensitivity and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women: the insulin resistance and atherosclerosis study A.J. KARTER, E.J. MAYER-DAVIS, J.V. SELBY, R.B. D'AGOSTINO, JR., S.M. HAFFNER, P. SHOLINSKY, R. BERGMAN, M.F. SAAD, AND R.F. HAMMAN FOR THE INSULIN RESISTANCE AND ATHEROSCLEROSIS STUDY INVESTIGATORS 1547

Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats J.-P. FULGENCIO, C. KOHL, J. GIRARD, AND J.-P. PEGORIER 1556

Regulation of rat liver glucose-6-phosphatase gene expression in different nutritional and hormonal states: gene structure and 5'-flanking sequence D. ARGAUD, Q. ZHANG, W. PAN, S. MAITRA, S.J. PILKES, AND A.J. LANGE 1563

Effect of troglitazone on insulin sensitivity and pancreatic  $\beta$ -cell function in women at high risk for NIDDM K. BERKOWITZ, R. PETERS, S.L. KJOS, J. GOICO, A. MARROQUIN, M.E. DUNN, A. XIANG, S. AZEN, AND T.A. BUCHANAN 1572

Plasma leptin levels correlate to islet function independently of body fat in postmenopausal women H. LARSSON, S. ELMSTÄHL, AND B. ARREN 1580

Metabolic consequences of a family history of NIDDM (The Botnia Study): evidence for sex-specific parental effects L. GROOP, C. FORSÉLOM, M. LEHTOVIRTA, T. TUOMI, S. KARANKO, M. NISSEN, B.-O. EHRNSTROM, B. FORSÉN, B. ISOMAA, B. SNICKARS, AND M.-R. TASKINEN, THE BOTNIA STUDY 1585



**ABSTRACT PREPARATION GUIDELINES****GENERAL INFORMATION**

1. Abstracts must be received at the Association's National Center by Monday, January 6, 1997.

2. Abstracts are not eligible if the paper has been presented at another national or international meeting or has been accepted for publication before the abstract submission deadline and will be published prior to the 57th Scientific Sessions. Failure to notify the Association of the publication of an abstract will result in a moratorium on the submission of abstracts for all authors appearing on the abstract in question for one year.

3. The printed abstract must be an original, submitted on the original abstract forms found in this packet. Abstracts cannot be submitted via fax.

4. An individual (member or non-member) may appear on four abstracts as an author, but may only appear as first author on two abstracts. A member may appear as author, co-author, or sponsor. A non-member may appear as author or co-author, but not as a sponsor. Authors are not required to be members of the Association.

5. Originality of work, adequacy of data, and clarity of exposition are the determinants in the selection of abstracts. Make abstracts as informative as possible, including a brief statement of the purpose of the study or why it was done, the methods or what was done, the results observed, and the author(s)' conclusions based on the results. Actual data should be summarized. It is inadequate to state "The results will be discussed" or "The data will be presented." Tables may be used to present data (refer to #18 in the instructions)

6. The final decision with respect to selection, programming, and/or publication of any abstract will be made by the Association's Scientific Sessions Meeting Committee.

7. Accepted abstracts will be printed as submitted. Changes to abstracts will not be accepted after submission. They should be carefully written and edited prior to submission.

8. For additional abstract packets, or if you have questions about completing the abstract form, contact Sandy DeVault, American Diabetes Association, 1660 Duke Street, Alexandria, VA 22314-3447, USA; phone: 703/549-1500, ext. 2096; FAX: 703/683-1839; E-mail: sdevault@diabetes.org.

9. Oral presentations at the Scientific Sessions will be limited to ten minutes each to allow time for discussion.

10. Expenses associated with the submission and presentation of the abstract are the responsibility of the presenter.

11. Presenters must pay the registration fee for attendance at the Scientific Sessions. Presenters will be able to register at pre-registration rates. For more information on registration, contact the Meeting Services Department, American Diabetes Association, 1660 Duke Street, Alexandria, VA 22314-3447, USA; phone: (703) 549-1500, ext. 2453 or 2330; FAX: (703) 683-1351; E-mail: meetings@diabetes.org.

**COMPLETING THE FORMS**

12. Accepted abstracts will be reduced by 25% and photographed as submitted for publication in the 57th Abstract Book, the May supplement to *Diabetes*. We recommend using a font no smaller than 10 points.

13. The text must be clear, within the border of the form, and limited to the space provided. Use only a typewriter or laser printer, as the quality of dot matrix printers varies considerably. Those with text exceeding the border will not be accepted. Text glued or taped inside the border will be accepted. Please use the following tips when printing your abstract:

■ If typed, use carbon ribbon or slightly used black silk ribbon (new ribbons smudge, old ones reproduce too faintly). Practice typing the abstract in a rectangle 4 3/16" (10.64 cm) X 6 3/16" (15.42 cm) before using the original form.

■ If using a laser printer, please note that the page size of the form is not standard. A left margin of 1.15" (2.92 cm) and a right margin of 3.35" (8.51 cm) should keep the text within the border. Practice printing the abstract with these margins before using the original form.

14. Abstract headings must follow a specified format. The format is as follows (refer to the example below):

a. Headings should begin to the immediate right of the box located in the upper left corner of the abstract area.

b. The first letters of major words in the title should be capitalized. Do not use subtitles (e.g., Methods, Results) in the abstract body.

c. Author(s)' complete first and last name(s) should be listed and capitalized. Authors who appear on more than one abstract should list their names the same way on all.

d. Author(s) who are members of the Association's Professional Section must be indicated by an asterisk (\*) after their name. No other identifying marks are permissible except as noted in "e." below.

e. Author(s) who indicate "yes" on the *Duality of Interest Disclosure Form* (see pg. 6) must include a notation after their name(s). Use the following to indicate the type of duality: 1 = any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or providers(s) of commercial services discussed in the educational presentation; 2 = any significant financial interest or other relationship with any commercial supporters of the activity.

f. Do not list credentials, degrees, academic title(s) (e.g., MD, RN, RD), departments, divisions, or institutional affiliation(s) on the abstract form.

g. Include city and state (postal abbreviations) or country of origin of work; do not include street address and zip code.

**Example of abstract heading:**

A Novel Form of Chelatin Prevents IDDM in BB Rats.  
JOHN DOE<sup>1</sup>, JAMES E. REASONER\*, SUSAN SMITH<sup>2</sup>,  
JANE FRIDAY<sup>2</sup>, Alexandria, VA

15. The first line of the text of the abstract and first line of any subsequent paragraphs should be indented three spaces.

16. The use of standard abbreviations is requested. Examples include kg, g, mg, ml, L (liter), meq, m (meter), mM (millimoles per liter), / (per), and % (percent). Place special or unusual abbreviations in parentheses after the full word the first time it appears, then use the abbreviation throughout the rest of the abstract. Use numerals to indicate numbers, except when beginning sentences.

17. Nonproprietary (generic) names should be used the first time a drug is mentioned and typed in lowercase letters; names are always capitalized, for example, aspirin (Bufferin).

18. Simple tables or special symbols may be included if they fit within the border of the form. Material that cannot be typed should be drawn in India ink.

19. Do not include references, credits, or grant support information in the abstract.

20. The Scientific Sessions Meeting Committee will consider presentation preference when planning the program. An abstract marked as "Only" (see Forms, pages 3 and 5) indicates that the authors do not want an abstract considered for any other type of presentation. For example, if an abstract is marked as "Oral Only" and is not selected for an oral presentation, the committee will not place the abstract in a poster session. Marking an abstract as "Oral Only" will not guarantee its selection for the program.

21. Categories for the 57th Scientific Sessions are located on page 4. Indicate the appropriate category under which you wish to have the abstract reviewed on both Form A and Form B. The Scientific Sessions Meeting Committee reserves the right to move an abstract that has been inappropriately categorized without notifying the author(s).

22. The signature of an active member of the Professional Section of the American Diabetes Association is required to validate the abstract. Members who sponsor non-members should verify that the latter are conforming to the rules. A member is not limited to the number of abstracts he/she can sponsor.

23. All authors must read and sign the *Duality of Interest* form (page 6) and this form must be included with each abstract submitted. Please refer to #14e for instructions on noting dualities on the abstract form. When preparing abstracts, please allow enough time to have all authors sign the original form.

24. Provide the information requested for the corresponding author, who will receive notification of abstract status (#28).

25. If the research presented in this abstract has been supported, in whole or in part, by a grant from the American Diabetes Association, please indicate so by checking on the appropriate line. Accepted abstracts with Association funding will be highlighted in the Final Program of the 57th Scientific Sessions. The response provided to this question will not affect the acceptance of abstracts for the 57th Scientific Sessions.

26. Before mailing an abstract submission, use the checklist on page 7 to confirm that all instructions have been followed and all items have been included in the submission packet.

## ACKNOWLEDGEMENT OF RECEIPT AND ABSTRACT STATUS

27. For acknowledgment that an abstract was received by the Association, you must provide a self-addressed, US stamped postal card addressed to the corresponding author. The reverse side of the card should indicate the title of the abstract. Confirmation of receipt cannot be made by phone.

28. A letter of notification and appropriate accompanying materials will be sent by mail to the corresponding author. In addition, all international correspondence will be sent by Internet E-mail or fax if the appropriate numbers are included on form A.

## MAILING SUBMISSION

29. A non-refundable processing fee of US \$35.00 and a completed payment form (see page 7) must accompany each abstract submitted to the American Diabetes Association. Payment must be in the form of a check or credit card. Checks must be in U.S. funds and drawn on a U.S. bank, and made payable to the *American Diabetes Association*. Major credit cards (American Express, VISA, MasterCard) are also accepted. Purchase orders and money orders will not be accepted.

30. The review of abstracts is blinded, therefore two forms must be submitted: one (1) for publication (Form A) with the title and author(s)' name(s) within the border of the form, and one (1) for review (Form B) without author information. Please refer to Abstract Forms A and B on pages 3 and 5 for further instructions.

31. Five (5) copies of the front only of each form must also be provided for processing.

32. Do not fold the originals or copies. They should be mailed FIRST CLASS or AIR MAIL, when applicable, and addressed as follows: Scientific Sessions Meeting Committee, American Diabetes Association, P.O. Box 26427, Alexandria, VA 22313-6427, USA. Abstracts sent by express mail should be addressed as follows: Scientific Sessions Meeting Committee, American Diabetes Association, 1660 Duke Street, Alexandria, VA 22314-3447, USA. When shipping express mail, do not ship for a Saturday arrival. Abstracts submitted via fax will not be accepted for review.

## "LATE-BREAKING RESEARCH" ABSTRACTS

33. Late-breaking research abstracts will be peer-reviewed, and only those deemed highly meritorious will be accepted for presentation. Selected abstracts will be presented during the President's Poster Session. "Late-breaking research" abstracts will not be published in the Abstract Book, nor will they appear in the Final Program because of printing deadlines. Authors should use the forms and follow instructions found in this packet. The appropriate box on Form A must be check marked, and all submissions must be received by May 16, 1997. The processing fee for abstracts in this classification is \$50. "Late-breaking research" abstracts must be sent to the attention of Sandy DeVault, American Diabetes Association, 1660 Duke Street, Alexandria, VA 22314-3447 USA. Notification of abstract status will be provided no later than May 30, 1997.



**TYPE ABSTRACT WITHIN BOX**

List family name, first name, middle initial, credentials/degrees, address (including city/state/country/zip), and telephone/fax numbers of author who should receive correspondence (please type or print):

Family Name \_\_\_\_\_

First Name \_\_\_\_\_ MI \_\_\_\_\_

Credentials/Degrees \_\_\_\_\_ Department \_\_\_\_\_

Institution \_\_\_\_\_

Street Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Country \_\_\_\_\_

Phones (include area code/country/city code): Work: \_\_\_\_\_ Fax: \_\_\_\_\_

Has this research been supported, in whole or in part, by a grant from the American Diabetes Association? \_\_\_\_\_ Y \_\_\_\_\_ N

Internet E-mail address: \_\_\_\_\_ (International submitters must include for timely notification)

**FOR OFFICE USE ONLY**

Date Rec'd \_\_\_\_\_ PMT? \_\_\_\_\_

Abstract No. \_\_\_\_\_

Duality? \_\_\_\_\_ Y \_\_\_\_\_ N Signed? \_\_\_\_\_ Y \_\_\_\_\_ N

Record No. \_\_\_\_\_

Mean Score \_\_\_\_\_



**FORM A**  
(For publication)

**CHECK ONE (See #21):**

- ☐ Poster Session Preferred      ☐ Oral Session Preferred  
☐ Poster Session Only      ☐ Oral Only  
☐ No Preference

The author's wishes will be followed if possible.

- ☐ I am submitting this abstract after January 6, 1997 as "late-breaking research" (See #33).

Abstract Category Number: \_\_\_\_\_  
(Categories listed on pg 4)

**IMPORTANT**

This form must be signed by an active member of the Professional Section of the American Diabetes Association.

The instructions on pages 1 and 2 must be followed exactly for abstracts to be considered for review.

The sponsoring member agrees that the material submitted herein conforms with the instructions on pages 1 and 2.

**MEMBER SIGNATURE**

**PRINTED NAME**

## TYPE ABSTRACT WITHIN BOX

Pramlintide, an Analog of Human Amylin  
Improves Glycemic Control in Patients with Type  
II Diabetes Requiring Insulin.

ROBERT THOMPSON\*<sup>1</sup>, LEEANNE PEARSON\*<sup>1</sup>, STEVEN  
SCHOENFELD\*<sup>1</sup>, ORVILLE KOLTERMAN\*<sup>1</sup>. San Diego, CA

The effects of 4 weeks of subcutaneous administration of pramlintide, (Pr) an analog of human amylin, on glycemic control in 203 patients with Type II diabetes mellitus requiring insulin were examined in a randomized, double-blind, placebo-controlled, parallel-group trial. Statistically significant reductions in serum fructosamine concentration were observed in the Pr 30 µg QID group ( $17.5 \pm 4.9$  µmol/L), the Pr 60 µg TID group ( $24.1 \pm 4.9$  µmol/L) and the Pr 60 µg QID group ( $22.6 \pm 4.1$  µmol/L) compared to placebo (PBO) ( $3.5 \pm 3.8$  µmol/L). There also were statistically significant shifts in the proportion of patients with an abnormal serum fructosamine concentration at baseline that normalized at Week 4 within the Pr 60 µg TID group (28%) and the Pr 60 µg QID group (31%) compared to PBO (10%). Consistent with the reduction in fructosamine, there were also statistically significant reductions in HbA<sub>1c</sub> in the Pr 30 µg QID group ( $0.53 \pm 0.07\%$ ), the Pr 60 µg TID group ( $0.58 \pm 0.07\%$ ) and the Pr 60 µg QID group ( $0.51 \pm 0.08\%$ ) compared to placebo ( $0.27 \pm 0.08\%$ ). Based on RBC lifespan, and assuming stable glycemic control, these reductions in HbA<sub>1c</sub> in the Pr groups should increase over the following 2-3 months. The reductions in fructosamine and HbA<sub>1c</sub> were accompanied by a statistically significant reduction in fasting total and LDL cholesterol. In contrast to treatment with insulin alone, there were trends towards decreased body weight in the Pr 60 µg TID and 60 µg QID groups. Furthermore, the incidence of hypoglycemia was no greater in any Pr group than in placebo. In conclusion, measurement of similar changes in both serum fructosamine concentration and HbA<sub>1c</sub> suggests that pramlintide therapy for 28 days improves glycemic control in patients with Type II diabetes mellitus requiring insulin.

## FOR OFFICE USE ONLY

Date Rec'd \_\_\_\_\_ PMT? \_\_\_\_\_

Abstract No. \_\_\_\_\_

Duality? \_\_\_\_\_ Y \_\_\_\_\_ N Signed? \_\_\_\_\_ Y \_\_\_\_\_

Record No. \_\_\_\_\_

Mean Score \_\_\_\_\_

FORM A  
(For publication)

## CHECK ONE (See #21):

- ☐ Poster Session Preferred ☒ Oral Session Preferred  
☐ Poster Session Only ☐ Oral Only  
☐ No Preference

The author's wishes will be followed if possible.

- ☐ I am submitting this abstract after January 6, 1997 as "late-breaking research" (See #33).

Abstract Category Number: 14  
(Categories listed on pg 4)

## IMPORTANT

This form must be signed by an active member of the Professional Section of the American Diabetes Association.

The instructions on pages 1 and 2 must be followed exactly for abstracts to be considered for review.

The sponsoring member agrees that the material submitted herein conforms with the instructions on pages 1 and 2.

Robert G. Thompson  
MEMBER SIGNATURE

R. Thompson  
PRINTED NAME

List family name, first name, middle initial, credentials/degrees, address (including city/state/country/zip), and telephone/fax numbers of author who should receive correspondence (please type or print):

Family Name ThompsonFirst Name Robert MI GCredentials/Degrees M.D. Department Clinical DevelopmentInstitution Amylin PharmaceuticalsStreet Address 9373 Towne Center DrCity San Diego State Ca Country U.S.A. Zip Code/Postal Code 92121Phones (include area code/country/city code): Work: 619-642-7133 Fax: 619-554-1472

Accepted for Oral Presentation

in part, by a grant from the American Diabetes Association? \_\_\_\_\_ Y X N



National Center  
1660 Duke Street  
Alexandria, Virginia 22314  
Tel: 703 549-1500  
Fax: 703 836-7439  
<http://www.diabetes.org>

To prevent and cure diabetes  
and to improve the lives of  
all people affected by diabetes.

March 17, 1997

**Officers**

Alan Altschuler  
*Chair of the Board*

Philip E. Cryer, MD  
*President*

Belinda P. Childs,  
RN, MN, CDE  
*President,  
Health Care & Education*

Stephen J. Satolino  
*Chair of the Board-Elect*

Mayer B. Davidson, MD  
*President-Elect*

Christine A. Beebe,  
MS, RD, CDE, LD  
*President-Elect,  
Health Care & Education*

Jane Camporeale  
*Vice Chair of the Board*

Gerald Bernstein, MD  
*Vice President*

Linda B. Haas,  
PhD, RN, CDE  
*Vice President,  
Health Care & Education*

Roger K. Towle  
*Secretary-Treasurer*

John H. Graham IV  
*Chief Executive Officer*

Robert G. Thompson, MD  
Clinical Development  
Amylen Pharmaceuticals  
9373 Towne Centre Dr.  
San Diego, CA 92121

Dear Dr. Thompson:

Congratulations! It is a pleasure to inform you that your abstract, *Pramlintide, an Analog of Human Amylin Improves Glycemic Control in Patients with Type II Diabetes Requiring Insulin*, has been selected for presentation at the Scientific Sessions of our 57th Annual Scientific Meetings and Sessions to be in Boston, Massachusetts from June 21-24, 1997. Your abstract, No. 0116, will also be published in the May 1997 supplement issue of *Diabetes*.

Your abstract was selected by the Scientific Sessions Meeting Committee from the over 1,500 abstracts submitted this year. It is currently scheduled to be presented as an oral presentation on Sunday, June 22 from 5:30-5:45 p.m. The room assignment has not been made yet, but will be shortly and we will forward that information to you.

Enclosed are appropriate instructions for your presentation and a Preliminary Program with registration and housing forms. Please complete the forms and return them as soon as possible to the address indicated. Since you will not receive this notification until after the March 14 pre-registration deadline, you will be allowed to register at the rate of \$260 for Association members or \$395 for non-members. Be sure to return your completed registration form by May 1. The registration form enclosed indicates that you are an abstract presenter.

In the event you are unable to attend the meeting due to unforeseen circumstances, please make arrangements to have a co-author present the abstract. If you are unable to make such arrangements or have any questions, contact Sandy DeVault, Manager, Professional Programs at 703/299-2096.

On behalf of the Scientific Sessions Meeting Committee, I would like to thank you for your contribution and effort.

Sincerely,

A handwritten signature in dark ink, appearing to read 'Dale L. Greiner'.

Dale L. Greiner, PhD  
Chair  
Scientific Sessions Meeting Committee

DG:sd  
Enclosures